GlassScriptPhysician profile
George Amyradakis
NPI 1013168657
$3,075.68
in general payments reported to CMS, 2019-2025
30 companies · $586 in 2025
The $586 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $84.41 · 2021: $462 · 2022: $861 · 2023: $414 · 2024: $365 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.86 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Astellas Pharma US INC | $320.82 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $293.84 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $266.16 | 2021-2025 | |
| Daiichi Sankyo INC. | $172.91 | 2019-2025 | Injectafer |
| Therapeuticsmd, INC. | $155.73 | 2019-2022 | |
| Gynesonics, INC. | $149.94 | 2022 | |
| Evofem Biosciences, INC. | $121.28 | 2021-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $117.14 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $104.33 | 2023-2025 | Myfembree |
| Pfizer INC. | $96.47 | 2019-2023 | |
| Smith+Nephew, INC. | $87.15 | 2020-2024 | Pico |
| Organon LLC | $79.62 | 2022-2024 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $59.60 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $50.56 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.68 | 2023-2025 | |
| Hologic Sales and Service, LLC | $41.99 | 2022-2023 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Convatec INC. | $36.24 | 2023-2025 | |
| Agile Therapeutics, INC. | $34.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.01 | 2019 | |
| Shield Therapeutics INC | $30.68 | 2024 | |
| Duchesnay USA Incorporated | $24.19 | 2019 | |
| Amgen INC. | $19.79 | 2024 | Evenity, Prolia |
| Lupin INC. | $19.43 | 2021 | |
| Biogen, INC. | $18.43 | 2025 | Zurzuvae |
| Endo Pharmaceuticals INC. | $15.56 | 2022 | |
| Minerva Surgical, INC | $14.75 | 2024 | |
| Amag Pharmaceuticals, INC. | $14.28 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.61 | 2019 | |
| Vivus LLC | $13.42 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Amyradakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.